Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Infant Bacterial Therapeutics AB ( ($SE:IBT.B) ) has shared an update.
Infant Bacterial Therapeutics AB has partnered with BioConnection to advance the production of their lead drug, IBP-9414, by initiating Process Performance Qualification at BioConnection’s facility in the Netherlands. This collaboration is crucial for securing IBT’s commercial supply chain and supports their market expansion, as BioConnection’s capabilities align with IBT’s mission to provide innovative therapies for premature infants, potentially saving lives and addressing unmet medical needs.
More about Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) is a pharmaceutical company based in Stockholm, focused on developing and commercializing drugs for diseases affecting premature babies. Their primary drug candidate, IBP-9414, is a Live Biotherapeutic Product derived from a bacterial strain in human breast milk, aimed at reducing mortality in premature infants. IBT’s portfolio also includes drug candidates targeting gastroschisis, retinopathy of prematurity, and vancomycin-resistant enterococci.
Average Trading Volume: 11,840
Technical Sentiment Signal: Sell
Current Market Cap: SEK597.5M
For detailed information about IBT.B stock, go to TipRanks’ Stock Analysis page.